Featuring perspectives from Dr Rashmi Chugh and Dr Richard F Riedel, including the following topics:

• Other Connective Tissue Neoplasms — Dr Chugh (0:00)
• Sarcoma — Dr Riedel (28:16)

CME information and select publications

Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:

• Introduction (0:00)
• CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer (mBC) — Dr Borges (9:56)
• Targeting the PTEN/PI3K/AKT Pathway in HR-Positive mBC — Dr Burstein (35:20)
• Role of Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive mBC — Dr O’Shaughnessy (1:03:07)
• Antibody-Drug Conjugates for HR-Positive mBC — Dr Bardia (1:36:12)

CME information and select publications

Featuring perspectives from Dr Nicole Lamanna and Dr Kerry Rogers, including the following topics:

• Introduction (0:00)
• Current Role of Covalent Bruton Tyrosine Kinase and Bcl-2 Inhibitors in Managing Chronic Lymphocytic Leukemia — Dr Lamanna (10:55)
• Novel Agents and Combination Strategies — Dr Rogers (31:21)

CME information and select publications

Featuring perspectives from Dr Simron Singh and Dr Jonathan Strosberg, including the following topics:

• Introduction (0:00)
• Initial Therapy for Advanced Neuroendocrine Tumors (NETs) — Dr Singh (6:48)
• Management of Progressive Advanced NETs — Dr Strosberg (28:50)

CME information and select publications

Featuring an interview with Dr Justin F Gainor, including the following topics:

• Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00)
• Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38)
• Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32)
• Tolerability profile of lorlatinib (23:28)
• Review of clinical investigator survey results (37:08)
• Novel ALK inhibitors under clinical development (53:22)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Justin F Gainor, including the following topics:

• Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00)
• Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38)
• Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32)
• Tolerability profile of lorlatinib (23:28)
• Review of clinical investigator survey results (37:08)
• Novel ALK inhibitors under clinical development (53:31)

CME information and select publications

Featuring an interview with Dr Adrienne G Waks, including the following topics:

• The Phase III AFT-38 PATINA trial of palbociclib combined with anti-HER2 therapy for hormone receptor (HR)-positive/HER2-positive metastatic breast cancer (mBC) (0:00)
• Role of immunotherapy in the treatment of breast cancer (8:30)
• Defining ER-low breast cancer and identifying treatment approaches for this histologic subtype (15:55)
• Genomic testing approaches for patients with localized breast cancer and identification of candidates for treatment with adjuvant olaparib (19:37)
• Current role of anthracyclines in the treatment of localized breast cancer (31:17)
• Available and novel antibody-drug conjugates for the treatment of breast cancer (41:21)
• Palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for HR-positive, HER2-negative mBC (51:53)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Adrienne G Waks, including the following topics:

• Updated analyses from key studies of the 21-gene Recurrence Score® for localized ER-positive breast cancer (29:30)
• Four-year landmark analysis of the NATALEE trial of adjuvant ribociclib with nonsteroidal aromatase inhibitor for localized breast cancer (9:49)
• The PADMA trial of palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (mBC) (11:25)
• Imlunestrant with or without abemaciclib for metastatic ER-positive mBC (13:18)
• TROP2-directed antibody-drug conjugates (ADCs) datopotamab deruxtecan and sacituzumab tirumotecan for HR-positive/HER2-negative mBC (17:50)
• Recent analyses from the DESTINY-Breast06 trial of trastuzumab deruxtecan (T-DXd) after endocrine therapy for HR-positive, HER2-low or HER2-ultralow mBC (21:09)
• The ICARUS-BREAST01 Phase II trial of the HER3-targeted ADC patritumab deruxtecan for HR-positive/HER2-negative mBC (26:02)
• Updates from neoadjuvant/adjuvant trials of pembrolizumab (KEYNOTE-522) and atezolizumab (NSABP B-59/GBG 96-GeparDouze) for localized triple-negative breast cancer (TNBC) (27:36)
• Ten-year update of the OlympiA trial of adjuvant olaparib for patients with germline BRCA1/2-mutated HER2-negative localized breast cancer (31:23)
• Exploratory analysis of patients who did or did not receive prior PD-1/PD-L1 inhibition in the Phase III OptiTROP-Breast01 study of sacituzumab tirumotecan versus chemotherapy for previously treated advanced TNBC (32:56)
• CNS efficacy of T-DXd (DESTINY-Breast12 trial) and outcomes with palbociclib combined with anti-HER2 therapy (AFT-38 PATINA trial) for HER2-positive mBC (34:04)

CME information and select publications

Featuring an interview with Dr Catherine C Coombs, including the following topics:

• Case: A woman in her early 80s with dementia and newly diagnosed IGHV-mutated del(13q) chronic lymphocytic leukemia (CLL) receives initial treatment with zanubrutinib (0:00)
• Current and investigational initial therapy approaches for CLL (13:41)
• Case: A man in his late 40s under observation for asymptomatic CLL develops worsening symptoms and initiates treatment with venetoclax/obinutuzumab (28:15)
• Phase III AMPLIFY trial of fixed-duration acalabrutinib combined with venetoclax with or without obinutuzumab as first-line treatment for CLL (36:02)
• Other novel venetoclax combinations for the treatment of CLL (43:36)
• Case: A man in his mid 70s with multiregimen-refractory CLL receives pirtobrutinib (46:51)
• Personal perspectives on the activity and tolerability of pirtobrutinib; sequencing pirtobrutinib and chimeric antigen receptor T-cell therapy for patients with CLL (51:16)

CME information and select publications

Featuring perspectives from Dr Kathleen N Moore, Dr David M O’Malley and Dr Alessandro D Santin, moderated by Dr O’Malley, including the following topics:

• Introduction (0:00)
• Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Santin (2:17)
• Available Data with and Practical Application of HER2-Targeted Therapy for Advanced Gynecologic Cancers — Dr O'Malley (30:24)
• Identification and Management of Adverse Events with Trastuzumab Deruxtecan — Dr Moore (1:01:53)

CME information and select publications